An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
as second-line treatment in metastatic prostate cancer, the present study will investigate
the efficacy of sunitinib (SUTENT) given orally at a dose of 37.5 mg continuously, for 6
cycles of 6 consecutive weeks .Patients who are still responders after 6 cycles will be
treated until disease progression, pain progression, unacceptable toxicity or death due to
any cause.
Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based
on individual safety and tolerability.
Follow-up for up to 1 year from the last dose of sunitinib.